The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data.

In Dermatology
by ClinOwl April 7, 2021

Data on the use of biologic therapy and malignancy risk are inconsistent due to limited long-term robust studies.To assess the malignancy risk in secukinumab-treated psoriasis, psoriatic arthritis (PsA) and ankylosing […]

U.S. Burden of Skin and Subcutaneous Diseases Increasing

Can dermatology employers require employees to receive the COVID-19 vaccine?

THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

Expression of retinoid receptors in hand eczema.

S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data.